China's first mRNA Covid-19 vaccine approved for clinical trials

2020-06-29
|
ChinaMedical

China's first mRNA Covid-19 vaccine approved for clinical trials

On June 28, Walvax Biotechnology announced that the company, as a co-notifying party, had recently received the "Drug Clinical Trial Approval" for the mRNA Covid-19 vaccine approved by the State Drug Administration.


The conclusion of the approval is that it is an emergency approval for the product for clinical trials, and the indication is to prevent diseases caused by SARS-CoV-2 infection (COVID-19).


The vaccine is China's first mRNA coronavirus vaccine approved for clinical trials.


At present, only Covid-19 mRNA vaccines from a few countries such as the United States and Germany have entered clinical trials.


RELATED ARTICLES

JD Health and AstraZeneca start strategic cooperation
2020-11-18
|
Medical care , Pharmaceutical

China Isotope & Radiation Corporation and Bayer agree to introduce Xofigo into China
2020-09-02
|
Pharmaceutical , Medical care

Xuanzhu Biopharm closes RMB 800 mln Series A
2020-08-27
|
Pharmaceutical , PEVC

Anti-body R&D company Escugen closes Pre-A raising tens of millions in RMB
2020-08-27
|
PEVC , Biotech , Pharmaceutical

China's first COVID-19 vaccine produced by insect cells obtained clinical trial approval
2020-08-24
|
Pharmaceutical , Vaccine , Covid-19 , Biotech

D2M Biotherapeutics completes $10 million Pre-A round of financing
2020-08-23
|
PEVC , Pharmaceutical , Biotech

Bio-Thera: BAT1308 injection received notification of clinical trial
2020-05-28
|
Healthcare , Pharmaceutical

New drug application of Paimpril accepted by State Drug Administration
2020-05-26
|
Biopharmaceutical , Medical care

Maccura Biotechnology's new coronavirus detection product obtains registration certificate
2020-05-18
|
Medical care , Pharmaceutical

Hengrui Medicine: Remazolam Tosylate for Injection Obtained Clinical Trial Notice
2020-05-14
|
Pharmaceutical
China SDG